PubMed

Beneficial effects of combined treatment with rosiglitazone and exercise on cardiovascular risk factors in patients with type 2 diabetes.

Kadoglou NP, Iliadis F, Liapis CD, Perrea D, Angelopoulou N, Alevizos M.

Diabetes Care. 2007 Sep;30(9):2242-4. Epub 2007 Jun 22. No abstract available. PMID: 17586747 [PubMed - indexed for MEDLINE]Related articlesFree article

Does pioglitazone prevent macrovascular events in patients with type 2 diabetes?

Hiralal R, Koo KK, Gerstein HC.

CMAJ. 2006 Apr 11;174(8):1090-1. No abstract available. PMID: 16606956 [PubMed - indexed for MEDLINE]Related articlesFree article

Early combination therapy with a thiazolidinedione for the treatment of type 2 diabetes.

Kanzer-Lewis G.

Diabetes Educ. 2003 Nov-Dec;29(6):954-8, 961. Review. No abstract available. PMID: 14692369 [PubMed - indexed for MEDLINE]Related articles

[The Steno-2 study. Intensive multifactorial intervention reduces the occurrence of cardiovascular disease in patients with type 2 diabetes]

Gaede PH, Jepsen PV, Larsen JN, Jensen GV, Parving HH, Pedersen OB.

Ugeskr Laeger. 2003 Jun 23;165(26):2658-61. Danish. No abstract available. PMID: 12886549 [PubMed - indexed for MEDLINE]Related articles

[Therapy with glitazones--a risk for cardiovascular disease?]

Rottlaender D, Michels G, Erdmann E, Hoppe UC.

Dtsch Med Wochenschr. 2007 Dec;132(49):2629-32. Review. German. PMID: 18050028 [PubMed - indexed for MEDLINE]Related articles

[Metabolic and hemodynamic effects of combined treatment with metformine and rosiglitasone (avandium) in patients with diabetes mellitus type 2 and high cardiovascular risk]

Demidova TIu, Erokhina EN.

Ter Arkh. 2007;79(10):39-45. Russian. PMID: 18154144 [PubMed - indexed for MEDLINE]Related articles

Beneficial effects of rosiglitazone on novel cardiovascular risk factors in patients with Type 2 diabetes mellitus.

Kadoglou NP, Iliadis F, Angelopoulou N, Perrea D, Liapis CD, Alevizos M.

Diabet Med. 2008 Mar;25(3):333-40.PMID: 18307460 [PubMed - indexed for MEDLINE]Related articles

[Rosiglitazone: a clinical development focused on cardio-vascular prevention]

Valensi P.

Ann Endocrinol (Paris). 2002 Apr;63(2 Pt 2):1S35-40. Review. French. PMID: 12037506 [PubMed - indexed for MEDLINE]Related articles

Introduction: the role of the thiazolidinediones in the cardiovascular risk management of type 2 diabetes.

Barnett AH.

Curr Med Res Opin. 2005;21 Suppl 1:S1-3.PMID: 15811193 [PubMed - indexed for MEDLINE]Related articles

Cardiovascular risk and TZD: safe therapy for the elderly?

Burt R, Townsend S, Armor B.

Consult Pharm. 2009 May;24(5):392-4.PMID: 19555148 [PubMed - indexed for MEDLINE]Related articles

[Assessment of the management of type 2 diabetes]

Hanaire-Broutin H, Després JP, Dubois-Randé JL, Grimaldi A.

Presse Med. 2004 Sep 25;33(16):1121-3. Review. French. No abstract available. PMID: 15523273 [PubMed - indexed for MEDLINE]Related articles

Thiazolidinedione derivatives in diabetes and cardiovascular disease: an update.

Sarafidis PA.

Fundam Clin Pharmacol. 2008 Jun;22(3):247-64. Epub 2008 Apr 15. Review.PMID: 18422634 [PubMed - indexed for MEDLINE]Related articles

A review of the United Kingdom Prospective Diabetes Study (UKPDS) and a discussion of the implications for patient care.

Srimanunthiphol J, Beddow R, Arakaki R.

Hawaii Med J. 2000 Jul;59(7):295-8, 313. No abstract available. PMID: 10961040 [PubMed - indexed for MEDLINE]Related articles

[Glitazones critically evaluated]

Schernthaner G.

Dtsch Med Wochenschr. 2007 Dec;132(49):2619. German. No abstract available. PMID: 18050024 [PubMed - indexed for MEDLINE]Related articles

Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in diabetes patients with Cardiovascular History (APPROACH): study design and baseline characteristics.

Ratner RE, Cannon CP, Gerstein HC, Nesto RW, Serruys PW, Van Es GA, Kolatkar NS, Kravitz BG, Zalewski A, Fitzgerald PJ; APPROACH Study Group.

Am Heart J. 2008 Dec;156(6):1074-9. Epub 2008 Oct 11.PMID: 19033001 [PubMed - indexed for MEDLINE]Related articles

Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10).

Wilcox R, Kupfer S, Erdmann E; PROactive Study investigators.

Am Heart J. 2008 Apr;155(4):712-7. Epub 2008 Feb 21. Erratum in: Am Heart J. 2008 Aug;156(2):255. PMID: 18371481 [PubMed - indexed for MEDLINE]Related articles

[Too positive comment on glitazones]

Lindberg M.

Ugeskr Laeger. 2007 Feb 19;169(8):733; author reply 733. Danish. No abstract available. PMID: 17338040 [PubMed - indexed for MEDLINE]Related articles

Pathophysiology of type 2 diabetes and its relationship to new therapeutic approaches.

Bell D.

Diabetes Educ. 2000 Nov-Dec;26 Suppl:4-7. Review. No abstract available. PMID: 11912815 [PubMed - indexed for MEDLINE]Related articles

Prevention of macrovascular disease in patients with diabetes mellitus: opportunities for intervention.

Mazzone T.

Am J Med. 2007 Sep;120(9 Suppl 2):S26-32.PMID: 17826043 [PubMed - indexed for MEDLINE]Related articles

Rosiglitazone for type 2 diabetes mellitus.

Richter B, Bandeira-Echtler E, Bergerhoff K, Clar C, Ebrahim SH.

Cochrane Database Syst Rev. 2007 Jul 18;(3):CD006063. Review.PMID: 17636824 [PubMed - indexed for MEDLINE]Related articles